Related Experiment Video
Updated: May 22, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Treatment of refractory catatonic schizophrenia with low dose aripiprazole
Tsuyoshi Sasaki1, Tasuku Hashimoto, Tomihisa Niitsu
1Department of Child Psychiatry, Chiba University Hospital, Inohana 1-8-1, Chiba, 260-8670, Japan. sasaki@faculty.chiba-u.jp.
Abstract:
This case is of 54-year-old female with catatonic schizophrenia, characterized by treatment resistance to the pharmacotherapy with olanzapine, risperidone, flunitrazepam, and ECT. Olanzapine and risperidone and flunitrazepam did not improve her catatonic and psychotic symptoms, and induced the extrapyramidal symptoms. The effects of ECT did not continue even for a month. However, the treatment with low-dose aripiprazole dramatically improved the patient's psychotic symptoms and extrapyramidal symptoms. The mechanisms underlying the effects of low-dose aripiprazole in this case remain unclear, but unlike other antipsychotics, aripiprazole is a dopamine D2 partial agonist. In this regard, our results suggest that aripiprazole has numerous advantages, especially in cases of stuporous catatonia and a defective general status.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Drug Therapy
Antianxiety Medications
Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Antidepressant Drugs: MAOIs and Other Agents